Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xun Wang, Xiao Li, Haifa Guo, Lingxiang Zhu, Zhiyong Peng, Jun Wang, Fan Yang & Yong Guo. (2020) Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer. OncoTargets and Therapy 13, pages 10621-10630.
Read now
Read now
Sang Hoon Lee, Eun Young Kim, Arum Kim & Yoon Soo Chang. (2020) Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. Cancer Biology & Therapy 21:8, pages 741-748.
Read now
Read now
Ilaria Attili, Niki Karachaliou, PierFranco Conte, Laura Bonanno & Rafael Rosell. (2018) Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy 18:10, pages 1021-1030.
Read now
Read now
Articles from other publishers (34)
Xiuwen Wang, Jizhen Liang, Li Li, Zhaojun Pan & Lin Wang. (2023) Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report. Anti-Cancer Drugs 34:2, pages 306-310.
Crossref
Crossref
Pang-Shuo Perng, Hui-Ping Hsu, Po-Hsuan Lee, Chi-Chen Huang, Chien-Chung Lin & Jung-Shun Lee. (2023) Correlation of EGFR mutation subtypes and survival in surgically treated brain metastasis from non-small-cell lung cancer. Asian Journal of Surgery 46:1, pages 269-276.
Crossref
Crossref
Yoshiya Matsumoto, Tomoya Kawaguchi, Masaru Watanabe, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Chiyoe Kitagawa, Naoki Yoshimoto & Yasuhiro Koh. (2022) Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer. BMC Cancer 22:1.
Crossref
Crossref
Weiting Li, Klaas Kok, Geok Wee Tan, Pei Meng, Mirjam Mastik, Naomi Rifaela, Frank Scherpen, T. Jeroen N. Hiltermann, Harry J. M. Groen, Anthonie J. van der Wekken & Anke van den Berg. (2022) The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare. Cancers 14:14, pages 3511.
Crossref
Crossref
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu & Chiao‐En Wu. (2022)
Epidermal growth factor receptor tyrosine kinase inhibitors for de novo
T790M
mutation: A retrospective study of 44 patients
. Thoracic Cancer 13:13, pages 1888-1897.
Crossref
Crossref
Sabrina Rossi, Paola Damiano, Luca Toschi, Giovanna Finocchiaro, Laura Giordano, Arianna Marinello, Emilio Bria, Ettore D'Argento & Armando Santoro. (2022) Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. Current Problems in Cancer 46:1, pages 100787.
Crossref
Crossref
Shohei NOGAMI, Susumu YOSHIOKA, Yuki HOSOKAWA, Miki MOCHIZUKI, Hirotake WAKAMATSU, Hiroshi TERASAKI & Mitsunobu SHIMADU. (2022) Amethod of Evaluation False-positive EGFR T790M Mutation Based on Deamining 5-methylcytosine5-メチルシトシンの脱アミノ化によるEGFR T790M変異偽陽性の評価方法. BUNSEKI KAGAKU 71:1.2, pages 59-68.
Crossref
Crossref
Ha-Ram Park, Tae Min Kim, Yusoo Lee, Soyeon Kim, Seongyeol Park, Young Seok Ju, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Dong-Wan Kim & Dae Seog Heo. (2021) Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC. Journal of Thoracic Oncology 16:11, pages 1859-1871.
Crossref
Crossref
Pilar Garrido, Luis Paz‐Ares, Margarita Majem, Teresa Morán, José Manuel Trigo, Joaquim Bosch‐Barrera, Rosario Garcίa‐Campelo, José Luis González‐Larriba, José Miguel Sánchez‐Torres, Dolores Isla, Núria Viñolas, Carlos Camps, Amelia Insa, Óscar Juan, Bartomeu Massuti, Alfredo Paredes, Ángel Artal, Marta López‐Brea, José Palacios & Enriqueta Felip. (2021) LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine 10:17, pages 5878-5888.
Crossref
Crossref
R. Saúde-Conde, S. Cristóvão-Ferreira, E. Campoa & M.T. Almodovar. (2021) Value of rebiopsy in advanced Epidermal Growth Factor Receptor mutated Non-Small Cell Lung Cancer: Real-world data. Pulmonology 27:2, pages 177-180.
Crossref
Crossref
Jie-Tao Ma, Yi-Jia Guo, Jun Song, Li Sun, Shu-Ling Zhang, Le-Tian Huang, Wei Jing, Jian-Zhu Zhao & Cheng-Bo Han. (2021) Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International 2021, pages 1-15.
Crossref
Crossref
Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan & Deepali Jain. (2020) Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. Lung Cancer 149, pages 53-60.
Crossref
Crossref
Linda Ye, Nima Mesbah Ardakani, Carla Thomas, Katrina Spilsbury, Connull Leslie, Benhur Amanuel & Michael Millward. (2020) Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. Pathology & Oncology Research 26:4, pages 2371-2379.
Crossref
Crossref
Amnah Sharif, Ann Shaji, May Chammaa, Eileen Pawlik & Rodrigo Fernandez-Valdivia. (2020) Notch Transduction in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 21:16, pages 5691.
Crossref
Crossref
Lei Lei, Wen‐xian Wang, You‐cai Zhu, Jin‐luan Li, Yong Fang, Hong Wang, Wu Zhuang, Yin‐bin Zhang, Li‐ping Wang, Mei‐yu Fang, Chun‐wei Xu, Xiao‐jia Wang, Tang‐feng Lv & Yong Song. (2020) Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study. Cancer Science 111:2, pages 679-686.
Crossref
Crossref
Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, Katsuhiko Nagase, Kenichi Yoshimura, Tadami Fujiwara, Azusa Tanimoto, Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Nobuyuki Katakami, Toshiaki Takahashi, Yoshinori Hasegawa, Tun Kiat Ko, S. Tiong Ong & Seiji Yano. (2020) Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer. Cancer Science 111:2, pages 561-570.
Crossref
Crossref
Yuan Tang, Nanying Che, Yang Yu, Yun Gao, Huaiyin Shi, Qin Feng, Bing Wei, Liheng Ma, Min Gao, Jie Ma & Dongmei Lin. (2019) Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. Journal of Cancer Research and Clinical Oncology 146:2, pages 407-416.
Crossref
Crossref
Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang & Jin-Yuan Shih. (2020) The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Therapeutic Advances in Medical Oncology 12, pages 175883592094615.
Crossref
Crossref
Burt P. Kotler & Joel S. Brown. (2020) Cancer Community Ecology. Cancer Control 27:1, pages 107327482095177.
Crossref
Crossref
Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Kazuto Hirata, Yasuhiro Koh & Tomoya Kawaguchi. (2020) Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer 139, pages 80-88.
Crossref
Crossref
J. Chantharasamee, N. Poungvarin, P. Danchaivijitr & S. Techawatanawanna. (2019) Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. BMC Cancer 19:1.
Crossref
Crossref
Daniela Iacono, Giorgia A. Osman, Maria R. Migliorino, Lucia Grillo, Daniele Remotti, Josè Nunnari, Serena Ricciardi, Antonio Rossi, Andrea Mancuso, Paolo Graziano, Angela Di Lorenzo, Monica Bronzini, Mauro Signora & Alvaro Leone. (2019) Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients. American Journal of Clinical Oncology 42:11, pages 845-850.
Crossref
Crossref
Ana C.Z. Gelatti, Alexander Drilon & Fernando C. Santini. (2019) Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 137, pages 113-122.
Crossref
Crossref
Susumu Noguchi, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Tomoko Tajiri, Tatsuyoshi Ikeue, Sadao Horikawa & Takakazu Sugita. (2019) Osimertinib Administration as the Primary Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy for Brain Metastasis of <i>De Novo</i> T790M-positive Lung Cancer. Internal Medicine 58:20, pages 3029-3031.
Crossref
Crossref
Ping-Chih Hsu, David M. Jablons, Cheng-Ta Yang & Liang You. (2019) Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences 20:15, pages 3821.
Crossref
Crossref
Julie A. Vendrell, Julien Mazieres, Romain Senal, Isabelle Rouquette, Xavier Quantin, Jean-Louis Pujol, Benoit Roch, Abdelali Bouidioua, Sylvain Godreuil, Etienne Coyaud, Pierre Brousset & Jérôme Solassol. (2019)
Ultra-sensitive
EGFR
T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring
EGFR
del19 Mutations and Treated with First-generation TKIs
. Clinical Cancer Research 25:14, pages 4280-4289.
Crossref
Crossref
Kohei Horiuchi, Takanori Asakura, Shinji Sakaguchi & Fumitake Saito. (2019) Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation. BMJ Case Reports 12:6, pages e229310.
Crossref
Crossref
Patricia E. Ganey & Sean A. Misek. 2019. Cellular Signal Transduction in Toxicology and Pharmacology. Cellular Signal Transduction in Toxicology and Pharmacology
73
111
.
Jennifer W Carlisle & Suresh S Ramalingam. (2019) Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology 15:8, pages 805-816.
Crossref
Crossref
Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu & Gee-Chen Chang. (2018) Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. Cancer Research and Treatment 50:4, pages 1164-1174.
Crossref
Crossref
Panwen Tian, Ye Wang, Weiya Wang, Yalun Li, Ke Wang, Xiaowei Cheng, Yuan Tang, Han Han-Zhang, Junyi Ye, Shannon Chuai & Weimin Li. (2018) High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation. Lung Cancer 124, pages 205-210.
Crossref
Crossref
José N. Minatta, Lorena Lupinacci, Gonzalo Recondo, Susana Sena, Gastón Boggio, Alejandro Muggeri, Carlos Rosenbrock, Federico Cayol, Martín Ángel, Miguel Muñoz, Susana Berutti, Nicolás Castagneris, Dolores Gómez Bradley & José M. Lastiri. (2018) Experiencia argentina del uso compasivo de osimertinib. Oncología Clínica 23:2.
Crossref
Crossref
Alexandra M. Haugh, Bin Zhang, Victor L. Quan, Erin M. Garfield, Jeffrey A. Bubley, Emily Kudalkar, Anna Elisa Verzi, Kara Walton, Timothy VandenBoom, Emily A. Merkel, Christina Y. Lee, Timothy Tan, Maria Cristina Isales, Betty Y. Kong, Alexander T. Wenzel, Christopher G. Bunick, Jaehyuk Choi, Jeffrey Sosman & Pedram Gerami. (2018) Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure. Journal of Investigative Dermatology 138:2, pages 384-393.
Crossref
Crossref
Elena D. Lavdovskaia, Aglaya G. Iyevleva, Anna P. Sokolenko, Natalia V. Mitiushkina, Elena V. Preobrazhenskaya, Vladislav I. Tiurin, Alexandr O. Ivantsov, Ilya V. Bizin, Liliya V. Stelmakh, Fedor V. Moiseyenko, Nina A. Karaseva, Sergey V. Orlov, Vladimir M. Moiseyenko, Marina A. Korzhenevskaya, Ivan A. Zaitsev, Andrey R. Kozak, Ivan V. Chistyakov, Andrey L. Akopov, Nikita M. Volkov, Alexandr V. Togo & Evgeny N. Imyanitov. (2018) EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. Oncology Research and Treatment 41:10, pages 634-642.
Crossref
Crossref